Search

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.

Read more

Publications

For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.

Read more

Chairs and Members

Chair:

Marc H. G. P. Raaijmakers, M. D. , Ph. D.

Read more

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more

Chairs and Members

ChairPieter Sonneveld (Rotterdam, The Netherlands)

Members
Niels Abildgaard (Odense, Denmark)
Meral Beksac (Ankara, Turkey)
Luca Berthamini (Rotterdam, Netherlands)
Lenka Bešše, Brno (Czech Republic)
Dr Bila (Belgrade, Serbia)
Nicole Brolli (Milano, Italy)
Sara Bringhen (Turin, Italy)
Mario Boccadoro (Turin, Italy)
Anna Maria Brioli (Bologna, Italy)
Annemiek Broyl (Rotterdam, Netherlands)—also Chair of Young…

Read more

SWG Educational Activities

In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

Highlights from the SWG

Participation in EHA and ASH congresses. Planning of new common trials. Conduct of annual EMSCO meeting in Nice in October 2023.

Read more